Avitide, Inc., the industry leader in the discovery, and manufacture of exclusive biopharmaceutical affinity purification solutions, today announced the closing of a Series E financing. Sands Capital Ventures, LLC led the financing round with participation from Mithril Capital Management, Polaris Partners, NeoMed Management, OrbiMed Advisors, and Borealis Ventures. Ian Ratcliffe (Sands Capital Ventures) joined Avitide’s Board of Directors.
